Dr. Mansoor Mohammed is a recognized authority in the fields of medical genomics and personalized medicine. He is the holder of several patents in the general fields of molecular diagnostics and genomics research. Dr. Mohammed completed his doctoral dissertation at the University of Guelph, Canada, majoring in both Molecular Immunology and Transgenic Technologies. He completed postdoctoral training in Clinical Cytogenetics at both UCLA and Baylor College of Medicine.
Dr. Mohammed co-founded Younique Genomics, served as the President and CEO of CombiMatrix Diagnostics—where he oversaw the development of one of the most comprehensive genomics testing menus in the diagnostic industry—and was the Director of Advanced Technologies at Quest Diagnostics, where he was honored with the Medical Innovation Award, the highest accolade given for excellence in medical research. Prior to his role at Quest Diagnostics, Dr. Mohammed was a founder and Director of Research and Development at Spectral Genomics. At Spectral Genomics, Dr. Mohammed pioneered the development of commercial Comparative Genomic Hybridization (CGH) array technologies and was responsible for the design and launch of the industry's first commercially available CGH arrays. He was the co-primary author of the first peer-reviewed study utilizing CGH arrays in the clinical diagnosis of developmental abnormalities (2002) and later (2008) was the senior author of the first peer-reviewed study utilizing CGH arrays for clinical oncology purposes. Moreover, the CGH array technologies Dr. Mohammed helped to innovate became the basis for the discovery of genome copy number variations (CNVs). The latter has fundamentally altered and improved the way the human genome is viewed and interpreted, and has spawned thousands of studies and publications worldwide.
Most recently, Dr. Mohammed has worked with leading medical practitioners to become one of the first in the world to incorporate genome CNV analyses into a comprehensive approach to personalized medicine. Dr. Mohammed's leadership of P3 Health represents the culmination of his many years as a diagnostics executive and pioneer in the field of medical genomics.